Complete clinical clearance at 12 weeks occurred in 10 of 74 patients ( 14 % ; 95 % CI , 6 % -21 % ) with placebo ; 11 of 72 ( 15 % ; 95 % CI , 7 % -24 % ) with low-dose treatment ; 17 of 74 ( 23 % ; 95 % CI , 13 % -33 % ) with middle-dose treatment ; and 22 of 70 ( 31 % ; 95 % CI , 21 % -42 % ) with high-dose treatment ( P = .01 ) .